Asthma News

There was a downward trend for asthma attacks and ED visits among Black adults and children relative to white patients during the COVID-19 pandemic, according to a letter published in Annals of Internal Medicine.

ANAHEIM, Calif. — A digital asthma self-management program reduced ED visit rates for adults with asthma on Medicaid, according to a presentation at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting.

Topline results from a phase 2b trial revealed that rademikibart led to improvements in lung function and asthma control in adults with moderate to severe persistent asthma compared with placebo.

ANAHEIM, Calif. —Patients with asthma used reliever inhalers more on days with unhealthy air quality during the Canadian wildfires, according to a poster at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting.

Adults with moderate to severe persistent asthma receiving rademikibart every 2 weeks showed greater improvements in lung function at week 12 compared with patients assigned placebo, according to topline results from a phase 2b trial.

China had a higher asthma mortality rate than the United States between 1990 and 2019, driven by smoking, high BMI and age, but this gap narrowed with time, according to a study published in the Chinese Medical Journal.

ANAHEIM, Calif. — Although disparities remain in asthma care, innovative strategies may close these gaps, according to a presentation at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting.

ANAHEIM, Calif. — Better biomarkers for diagnosis and prognosis are needed for better personalized asthma care, according to a presentation at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting.

The historical climate events of the past summer may have been eye-opening for all, but the health of patients with respiratory diseases and conditions has been particularly threatened due to these exposures.

Sputum neutrophil percentage and levels of eotaxin-1, IL-5 and eosinophil peroxidase may be used to predict remission among patients with severe asthma 1 year after anti-IL-5 therapy, according to a study published in CHEST.